Postoperative Pain After Breast Reconstruction With Abdominal Flap Clinical Trial
— Fentanyl PatchOfficial title:
Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction
| Verified date | December 2010 |
| Source | University of California, San Francisco |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The aim of this randomized, double-blind controlled trial is to determine the efficacy of transdermal fentanyl for the management of early postoperative pain in women undergoing mastectomy followed by immediate TRAM or DIEP flap reconstruction. We will examine whether the use of the fentanyl patch as a bridge between epidural and oral analgesia will improve overall pain relief compared to placebo patch. We further propose to study whether the fentanyl patch is associated with improved ability to sleep, patient satisfaction, and functional capacity at one week, and whether it is associated with different side effects than standard therapy without the patch. Following informed consent, patients will undergo mastectomy and reconstruction, and receive epidural fentanyl for initial postoperative analgesia. Patients will be randomized to active (25 mcg/hr Duragesic) or placebo patches on postoperative day three, and the epidural will be weaned over the next 12 hours. Pain intensity scores and relief from pain will be assessed every day while in the hospital and oral and IV opioid use recorded. Patients will be discharged to home with a supply of 2 patches and oral medication, and will be asked to fill out a daily pain and medication log.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | August 2007 |
| Est. primary completion date | August 2007 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Undergoing breast reconstruction with abdominal flap - Provided written, informed consent Exclusion Criteria: - Karnofsky performance status =80% |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of California, San Francisco | San Francisco | California |
| Lead Sponsor | Collaborator |
|---|---|
| University of California, San Francisco |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Opioid analgesic use | Daily opioid use on immediate postoperative days while wearing patch | 10-20 days | |
| Secondary | Pain intensity | Daily measure of pain intensity on 0-10 numeric rating scale on postoperative days | 10-20 days | |
| Secondary | Relief from pain | Daily measure of relief provided by pain medications on 0-100% scale on postoperative days | 10-20 days | |
| Secondary | Adverse event questionnaire | Daily measurement of headache, itching, nausea, vomiting, constipation, difficulty urinating, drowsiness, lightheadedness, indigestion | 10-20 days | |
| Secondary | Functional assessment questionnaire | Daily measure of how surgical pain has interfered with general activity, mood, walking ability, sleep, brushing teeth, interactions with other people and enjoyment of life on a 0-10 scale on postoperative days | 10-20 days |